Liminatus Pharma initiates strategic review of blockchain-integrated strategy

Liminatus Pharma (LIMN) has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of its broader treasury management framework. This internal review is part of Liminatus’s continued commitment to strong financial stewardship and balance sheet optimization. While its core focus remains firmly on advancing cancer therapies, the Company believes it is prudent to assess innovative financial instruments-including blockchain-based assets-that may enhance treasury efficiency and diversify non-operating capital reserves.